scholarly journals Is the newest angiotensin‐receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta‐analysis

2021 ◽  
Author(s):  
Ji‐Guang Wang ◽  
Miao Zhang ◽  
Ying‐Qing Feng ◽  
Chang‐Sheng Ma ◽  
Tzung‐Dau Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Blood Pressure ◽  
Angiotensin Receptor Blocker ◽  
Meta Analysis ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Azilsartan Medoxomil

scholarly journals Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension

Hypertension ◽  
2011 ◽  
Vol 57 (3) ◽  
pp. 413-420 ◽  
Author(s):  
William B. White ◽  
Michael A. Weber ◽  
Domenic Sica ◽  
George L. Bakris ◽  
Alfonso Perez ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Angiotensin Receptor Blocker ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Clinic Blood Pressure ◽  
Azilsartan Medoxomil

scholarly journals The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Jiuyang Xu ◽  
Yaqun Teng ◽  
Lianhan Shang ◽  
Xiaoying Gu ◽  
Guohui Fan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Angiotensin Converting Enzyme ◽  
Angiotensin Converting Enzyme Inhibitor ◽  
Angiotensin Receptor Blocker ◽  
Enzyme Inhibitor ◽  
Meta Analysis ◽  
Receptor Blocker ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitor

Abstract There have been arguments on whether angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) treatment alters the risk of coronavirus disease 2019 (COVID-19) susceptibility and disease severity. We identified a total of 102 eligible studies for systematic review, in which 49 studies adjusting for confounders were included in the meta-analysis. We found no association between prior ACEI/ARB use and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the general population (adjusted odds ratio [aOR], 1.00; 95% confidence interval [CI], .94–1.05). The risk of mortality (aOR, .87; 95% CI, .66–1.04) and severe outcomes (aOR, .95; 95% CI, .73–1.24) were also unchanged among COVID-19 patients taking ACEIs/ARBs. These findings remained consistent in subgroup analyses stratified by populations, drug exposures, and other secondary outcomes. This systematic review provides evidence-based support to current medical guidelines and position statements that ACEIs/ARBs should not be discontinued. Additionally, there has been no evidence for initiating ACEI/ARB regimen as prevention or treatment of COVID-19.

scholarly journals Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension

2018 ◽  
Vol 24 (1) ◽  
Author(s):  
Attila Juhasz ◽  
Jingtao Wu ◽  
Michie Hisada ◽  
Tomoka Tsukada ◽  
Myung Ho Jeong
Keyword(s):  
Essential Hypertension ◽  
Angiotensin Receptor Blocker ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Efficacy And Safety ◽  
Korean Patients ◽  
Azilsartan Medoxomil

scholarly journals COVID-19 PANDEMIC AND MANAGEMENT OF HYPERTENSION

2021 ◽  
Vol 54 (3) ◽  
pp. 275-276
Author(s):  
Kanwal Ashiq ◽  
Sana Ashiq
Keyword(s):  
Systematic Review ◽  
Blood Pressure ◽  
Ace Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Meta Analysis ◽  
Lung Cells ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Receptor Blockers ◽  
Hypertensive Therapy

Dear Editor, In December 2019, a new virus which is known as SARS-COV-2 (COVID-19) was identified. In a short period, this virus spread rapidly and caused significant morbidities and mortalities across the earth. On March 11, 2020, the World Health Organization (WHO) declared a pandemic due to the logarithmic expansion of COVID-19 cases globally.1 Various guidelines were issued, and a complete lockdown has been observed on a large scale to stop the spread of the virus. Currently, there is no specific treatment for COVID-19 is available. Throughout the year 2020, scientists struggled a lot to find the COVID-19 cure, and many vaccines are successfully developed which would be helpful in the prevention of disease. Nevertheless, the emergence of virus variants remains an issue. The epidemiological trends and clinical features of this disease have been reported in several publications.2 Due to comorbidities, COVID-19 disease can exacerbate and may result in increased severity and deadly consequences. In a study, the most common comorbidities in COVID-19 patients were reported as following; diabetes (19%), hypertension (30%), and coronary heart disease (8%). In hypertension, blood pressure elevates from the threshold level. The occurrence of hypertension is not necessarily to be associated with COVID-19 as hypertension is quite frequent in geriatric patients, and these patients are at higher risk of being infected with COVID-19.3,4 Angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors are widely prescribed for the cure of hypertension and other cardiovascular-related diseases. On the other hand, the COVID-19 virus binds with ACE2 to gain entry into the lung cells. ACE inhibitors and ARBs escalate ACE2 that could hypothetically increase the chance of COVID-19 binding to lung cells and could headway to more damage. Conversely, in experimental studies, ACE2 showed a protective effect against lung injury. Due to the anti-inflammatory potential of ACE inhibitors and ARBs, these agents can reduce the incidence of developing myocarditis and acute respiratory distress syndrome in COVID-19 patients. There is no evidence that hypertension is linked with the COVID-19 and anti-hypertensive medicines (ACE inhibitors and ARBs) are either harmful or beneficial during the COVID-19 pandemic.5 During this unprecedented situation, the Council on Hypertension of the European Society of Cardiology released a statement that “The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest that treatment with ACEIs or ARBs should be discontinued because of the COVID-19 infection.” After this announcement, many other societies also recommend that patients should continue using their current hypertensive therapy and if necessary, after careful assessment, changes can be made in the hypertensive regimen.6 According to estimation, globally, 1.5 billion people can suffer from hypertension by 2025 which may contribute approximately 75% of stroke risk and 50% of heart disease risk. CVDs accounts almost 38% of deaths related to the non-communicated disease (NCDs). In Pakistan, hypertension is a chief health concern that leads to significant morbidity and mortality. Blood pressure can be control with medications and lifestyle modifications. One of the best approaches to control and improve blood pressure is team-based care consisting of doctors, pharmacists, and nurses. During COVID-19, collaborative efforts are required to improve patient’s quality of life and to reduce the healthcare burden.7,8 Keywords: COVID-19, Hypertension, Pandemic, ACE inhibitors References Ashiq K, Bajwa MA, Ashiq S. COVID-19 Pandemic and its Impact on Pharmacy Education. Turkish J Pharma Sci. 2021;18(2):122. Ashiq K, Ashiq S, Bajwa MA, Tanveer S, Qayyum M. Knowledge, attitude and practices among the inhabitants of Lahore, Pakistan towards the COVID-19 pandemic: an immediate online based cross-sectional survey while people are under the lockdown. Bangladesh J Med Sci. 2020:69-S 76. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. Ashiq S, Ashiq K. The Role of Paraoxonase 1 (PON1) Gene Polymorphisms in Coronary Artery Disease: A Systematic Review and Meta-Analysis. Biochem Genet. 2021:1-21. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Am J Hypertens. 2020;33(5):373–374. Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA. 2020;323(18):1769-70. Riaz M, Shah G, Asif M, Shah A, Adhikari K, Abu-Shaheen A. Factors associated with hypertension in Pakistan: A systematic review and meta-analysis. PLoS One. 2021;16(1):e0246085. Zarei L, Karimzadeh I, Moradi N, Peymani P, Asadi S, Babar Z-U-D. Affordability assessment from a static to dynamic concept: a scenario-based assessment of cardiovascular medicines. Int J Environ Res Public Health. 2020;17(5):1710.

scholarly journals Is Renoprotection by Angiotensin Receptor Blocker Dependent on Blood Pressure?: The Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) Study

2007 ◽  
Vol 30 (6) ◽  
pp. 529-533 ◽  
Author(s):  
Shigehiro KATAYAMA ◽  
Shinji YAGI ◽  
Hitoshi YAMAMOTO ◽  
Masako YAMAGUCHI ◽  
Taro IZUMIDA ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Medical School ◽  
Angiotensin Receptor Blocker ◽  
Receptor Blocker ◽  
Angiotensin Receptor
Sign in / Sign up

Export Citation Format

Share Document